Educational Activity

This collection from Psychiatrist.com News highlights the latest developments in schizophrenia treatment, emphasizing new therapies that go beyond traditional dopaminergic approaches. Clinicians will gain insights into managing symptoms, cognitive...

Among the greatest unmet needs in MDD is for effective pharmacotherapies for patients who do not respond to first- and second-line antidepressant medications. After decades of muted progress, alternatives...

Research on neuroactive steroids reveals their role in perinatal depression, leading to development of novel therapeutics. These emerging treatments hold promise for faster onset and lasting effects.  

While patients with ADHD today still face numerous unmet needs, a number of newer pharmacologic agents and devices with potential advantages over traditional therapies have emerged and gained regulatory...

FDA-approved medications and early intervention for people with substance use disorders should be encouraged as early as possible to optimize patient outcomes and life expectancy.

Next generation therapeutics that work well, are better tolerated, and lead to improved outcomes may offer a different treatment approach for patients with schizophrenia.